269 related articles for article (PubMed ID: 12360470)
1. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.
Chen YC; Sheen IS; Chu CM; Liaw YF
Gastroenterology; 2002 Oct; 123(4):1084-9. PubMed ID: 12360470
[TBL] [Abstract][Full Text] [Related]
2. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
[TBL] [Abstract][Full Text] [Related]
4. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
6. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
8. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection.
Chen YC; Jeng WJ; Chien RN; Chu CM; Liaw YF
Aliment Pharmacol Ther; 2016 Jun; 43(12):1311-8. PubMed ID: 27072504
[TBL] [Abstract][Full Text] [Related]
10. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
Choi J; Yoo S; Lim YS
Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of delayed clearance of serum HBsAG in patients with chronic HBV infection.
Nam SW; Jung JJ; Bae SH; Choi JY; Yoon SK; Cho SH; Han JY; Han NI; Yang JM; Lee YS
Korean J Intern Med; 2007 Jun; 22(2):73-6. PubMed ID: 17616021
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
14. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen.
Tong MJ; Nguyen MO; Tong LT; Blatt LM
Clin Gastroenterol Hepatol; 2009 Aug; 7(8):889-93. PubMed ID: 19394445
[TBL] [Abstract][Full Text] [Related]
15. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma.
Kim JH; Lee YS; Lee HJ; Yoon E; Jung YK; Jong ES; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Clin Gastroenterol; 2011 Jan; 45(1):64-8. PubMed ID: 20535028
[TBL] [Abstract][Full Text] [Related]
16. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
[TBL] [Abstract][Full Text] [Related]
17. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
Park YM; Lee SG
World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
[TBL] [Abstract][Full Text] [Related]
20. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
